The relationship of a regimen’s toxicity is dynamically related to its efficacy. As the regimens become more efficacious, more patients are willing to accept the risk of toxicity. Equally important, as the regimens become less toxic, the number of patients willing to undergo treatment increases. These treatment decision dynamics remain in constant flux as we move toward a curative regimen for early myeloma.